1 / 13

ISPOR International Initiatives on the Assessment of the Value of Medical Technologies

Explore the role of HTA, cost-effectiveness, and other assessment tools in evaluating the value of medical technologies globally and locally. This study aims to build a platform for dialogue among stakeholders in the field.

dmackenzie
Download Presentation

ISPOR International Initiatives on the Assessment of the Value of Medical Technologies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies Amy Pavlock, VMD Carlo Federici, MSc Oriana Ciani, PhD, MSc Friday, 14 December, 2018

  2. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies • Objectives: • Identify the current and possible future role of HTA, cost-effectiveness and budget affordability metrics, and other tools/approaches/methods used to assess the value of medical technologies’ continuous, disruptive transformative innovation globally and locally • Present reflections on the future role that HTA and other tools could have in assessing medical technologies throughout their lifecycle to inform adoption/reimbursement or local decisions and health care policies • A long-term objective may involve building up a platform for continuous dialogue at an international level between interested stakeholders in the field of medical technologies

  3. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies • Methods: • Gap analysis focusing on assessment of the value of medical technologies, including the role of HTA, at different stages of the lifecycle via a systematic literature review using 2 research questions: • What is the literature on assessment of the value of medical technologies at different stages of the product lifecycle and what is the role of HTA in determining/assessing value? • Are there identifiable differences in the role of HTA assessing the value of medical devices? • Subsequent conduct of survey/mapping designed to complement the systematic overview where needed

  4. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies • Two reviewers from NICE UK and ISPOR independently screened the identified records • a 3rd reviewer was consulted to reconcile the differences between the initial reviewers • Preliminary data extraction from included abstracts was performed

  5. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies Information retrieved from included papers (I) • Objective of Study • Type of Study • Country(ies)/ Region(s) • Type of Medical Technology • Medical Technology Lifecycle Stage(s) • Type of Value Assessment The aim of the study empirical, methodological, qualitative/surveys, model-based Formal HTA, clinical performance, economic performance, broadensocietal impact etc. Early (before market access), middle (at launch), late, whole lifecycle Jurisdictionswhere the assessmentwasdone Medical device, diagnostic, m-Health, etc.

  6. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies Information retrieved from included papers (II) • Organization Performing Value Assessment • Type(s) of Evidence Collected • Methods used for assessment • Conclusions • Limitations Name and type of organization (HTA agency, SHI, private companies etc.) Clinicaleffectiveness, performance, safety, costs, etc. Limitation of the study MCDA, modelling, mixed methods etc. Summary of conclusionsrelating to valueassessment of MDs, barriers and facilitating factors

  7. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies • Preliminary results (I)

  8. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies • Preliminary results (II)

  9. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies • Preliminary results (III) Conclusions: • Growing experience and literature in the assessment of the value for medical technologies • Most of the studies are commentariesunspecific with respect to type of technologies, stage of lifecycle development, geographic region • More applied studies refer directly to high income setting, device/diagnostics types of products, and early stage of development • Wide scope raiseschallenges in focus for this review

  10. ISPOR International Initiatives on the Assessment of the Value of Medical Technologies • Next Steps: • Ultimate full-text data extraction and provide a critical overview of methods and roles of value assessment framework in the literature • Invite additional international agencies, individuals, and/or regions to participate in this project • Conduct interviews to integrate the results of the review • Provide policy recommendations on the future role that HTA and other tools could have in assessing medical technologies

  11. Acknowledgments Thank you for your attention. oriana.ciani@unibocconi.itcarlo.federici@unibocconi.itamy.pavlock@ispor.org • Adriana Velazquez Berumen • Carlo Federici, MSc • Finn Børlum Kristensen, MD, PhD • Giuditta Callea, PhD • Julie Polisena, PhD, MSc • Leandro Pecchia, PhD • Mirella Marlow, MBA, MA • Oriana Ciani, PhD, MSc • Øyvind Melien, MD, PhD, MSc

  12. Disclosure • No funding has been supplied for this project and there are no conflicts of interest for any participants.

More Related